0
0
0
s2sdefault

On July 26 it was announced that Matthew Holman, director of the Office of Science (OS) in the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP), was leaving the agency to work for Philip Morris International (PMI).

 

There have been valid concerns that this is an example of a political revolving door.  But, Holman’s contributions to the tobacco and nicotine debate in recent years seems to suggest he was increasingly a square peg in a round hole at the FDA during his 20 years at the agency.